MMS reaches an employee training milestone of 700 pharma industry courses
Canton, Mich. (April 13, 2018) – MMS Holdings Inc. (MMS) – a global, leading clinical research organization – announced today that it has surpassed a training milestone, now with more than 700 training courses available in their learning management system. This platform offers education to all MMS colleagues across North America, Europe, India, and South Africa in a variety of formats from instructor led to self-directed sessions.
Each of the courses has been developed in-house, and expertise in the data sciences and clinical research arenas has led MMS to provide training outside of the organization to research sponsor teams as well. MMS staff provides training to sponsors on New Drug Application (NDA) submissions planning and best practices, as well as clinical trial disclosure topics on a routine basis, among other training.
“One of our most important assets is the people that work at MMS throughout the world, with their data and science–first mindset and unmatched drive to meet our customer’s needs,” said Michelle Gayari, Head of Global Operations, MMS. “From the onset, MMS has been an organization focused on compliance and strength of process, and a key component is supporting each colleague’s need to be continually learning and stretching within this fast-paced industry.”
To further this dedication to education and talent development within the research community and pharmaceutical and life sciences industries, the company created MMS Academy to serve the continuing education needs of students, recent graduates, and current working professionals.
“As an instructor, it is incredibly rewarding to be passing on nearly 30 years of industry knowledge,” said Chris Hurley, Senior Manager, Global Data Operations, Standards and Systems, MMS, and clinical programming instructor, MMS Academy. “Continual learning is a key trait for any effective leader, and we are proud to bring this to the future leaders in pharma.”
Beyond clinical programming, areas of focus include medical and regulatory writing, biostatistics, clinical trial disclosures, pharmacovigilance, use of real world evidence, and more.
Follow the MMS journey at https://www.linkedin.com/company/mms-holdings-inc-/
About MMS
MMS is a global, leading clinical research organization that supports the pharmaceutical and biotech industries with a proven, scientific approach to complex regulatory submission challenges. As a data CRO, we are pioneers and leaders in regulatory submissions for our sponsors. Strong industry experience and a data-driven approach to drug development make MMS a valuable partner in creating compelling submissions that meet rigorous regulatory standards.
About MMS Academy
MMS Academy offers students and working professionals continuing education opportunities that enhance their skills and expertise. Providing both theory and hands-on experience, the courses offered educate students on the complexities and requirements for professionals in the medical writing, clinical programming and clinical trial disclosure disciplines. Created by subject matter experts and a leading global CRO, MMS Academy empowers students with the critical in-demand knowledge the pharmaceutical industry requires. For more information, visit: www.mmsacademy.com
Suggested For You
news
February 2nd, 2022
MMS Holdings Only Michigan Pharma Organization Awarded a 2022 Top Workplace USA Recognition
news
November 15th, 2021
MMS Holdings is the Winner of The Michigan Top Workplaces 2021 Award
news
July 15th, 2021
Health Data Research UK Selects MMS as Data Services Partner for the International COVID-19 Data Alliance
news
January 29th, 2021
MMS Holdigns Joins DTRA as A Founding Member to Accelerate The Adoption of Patient- Focused
news
March 4th, 2020
MMS Holdings To Debut Datacise Integrated Safety Explorer To Detect Safety Signals
news
January 25th, 2019
BREAKING NEWS: MMS partners with MIT Julia Lab and University of Maryland to create the Health Analytics Collective
news
November 2nd, 2018
Chris Hurley Asked to Renew Three-Year Term as Americas Director of Leading Data Sciences Organization PhUSE
news
September 26th, 2017
Pfizer Selects MMS as Preferred Provider for Plain Language Summary Writing Support

fact sheet
July 9th, 2025
Comments Open for Postapproval Manufacturing Changes to Biosimilar

whitepaper
June 27th, 2025
Together Trial with EDC Database Designed by MMS Wins Trial of the Year
webinar
September 26th, 2024
Regulatory Pathways for Nonprescription Drugs: A Deep Dive into OTC Monograph Reform and FDA Guidance
regulatory intelligence
June 26th, 2024
New Details on Diversity Action Plans Provided by the US FDA